Date: Thursday, July 13, 2023
Time: 2:00pm – 3:00pm ET

TOPIC:
Gene Therapy Update
OBJECTIVES:
- Review the status of Roctavian and Hemgenix, gene therapy products and the Alliance contracts with the Biomarin and CSL.
- Provide information on how to obtain the products and ensure they are infusion ready.
- Examine the rationale behind Biomarin’s decision to use Specialty Pharmacies and TAP for distribution and discuss how using TAP would benefit Hemophilia Treatment Centers (HTCs).
- Conduct a comprehensive review of the Alliance Contract with CSL and Biomarin.
- Compare and analyze the pricing model and rebate program offered by Biomarin and CSL, specifically in relation to gene therapy products.
We encourage you to submit questions ahead of time you would like to be answered or are just curious about.
SPEAKER:

Joe Pugliese, President & CEO Hemophilia Alliance